Guest guest Posted March 30, 2011 Report Share Posted March 30, 2011 A well-known CLL expert has told me that he feels that CAL-101 has been over-hyped. He thinks that it may find a place in CLL, probably in combination with another drug(s). He thinks it is sad that the drug is touted as the next coming, when it affects only one part of the pathway affecting lymphocyte activation, and that the cancer cell eventually finds another way of stimulating that pathway. I tend to agree that we all get way too excited when there is a new drug out there. I remember the same thing happening when the 'smart bomb' of rituximab came out. Then reality set in. Same thing will happen with these newer drugs. Guess that is why FCR and other mainstays haven't gone away. Nor will they, anytime soon. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.